Prostate Cancer International is
for 2011 by Great NonProfits
We have known for a while that men with a tertiary Gleason grade of 4 or 5 (as discussed below) are at heightened risk for progressive forms of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: Gleason, grade, pattern, prognosis, risk, tertiary | 1 Comment »
Two recent papers from a clinical research team at the University of Western Ontario in Canada have offered us insights into the appropriate usage of cryoablation as salvage therapy for men with progressive (recurrent) prostate cancer after first-line treatment for localized and locally advanced prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: cryotherapy, outcome, prognosis, salvage | Leave a Comment »
The NADiA® ProsVue™ test is a highly sensitive investigational PSA immunoassay.
Filed under: Living with Prostate Cancer | Tagged: prognosis, progression, ProsVue, PSA | Leave a Comment »
There has been little doubt over the years that prostate cancer was a genetically complex disease. No one has ever seriously thought that prostate cancer was the result of a single change in the DNA of the individual patient. Now we finally have some proof!
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: Diagnosis, genome, prognosis, risk | 3 Comments »
A new report just published on line in Lancet Oncology is suggesting that the cell cycle progression (CCP) score — a measure of the levels of expression of selected genes that are important to cell growth — may be an important indicator of risk for more aggressive types of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, CCP, cell cycle progression, prognosis, PROLARIS, score | Leave a Comment »
A recent French study nicely illustrates the very real problem associated with the selection of the best candidates for active surveillance and the exclusion from active surveillance of patients who probably would be better served by immediate treatment.
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, criteria, prognosis, selection | 6 Comments »
One of the problems with prostate cancer is that it can take many years for the disease to develop from a very small group of cells in a man’s prostate into a disorder that has actual clinical significance.
Filed under: Diagnosis, Risk | Tagged: clinically significant, early stage, ethics, Malmo, prognosis, trial | Leave a Comment »
About 7 months ago we commented on an Italian study of the association between perineural invasion (PNI) on biopsy and outcomes after first-line surgical treatment for localized prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: perineural invasion, PNI, prognosis, risk | Leave a Comment »
Earlier studies based on data from Johns Hopkins and the Center for Prostate Disease Research have shown that PSA doubling times are strongly associated with risk for metastasis, prostate cancer-specific, and overall mortality.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, prognosis, PSA, PSADT, risk | 3 Comments »
Work by Bostwick and his colleagues (long before the development of Bostwick Laboratories) first showed a clear association between an initial diagnosis of high-grade prostatic intraepithelial neoplasia (HG-PIN) and subsequent risk for a diagnosis of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, HG-PIN, high-grade, outcome, prognosis, progression, prostatic intraepithelial neoplasia | 2 Comments »
According to a new report from the University of California, San Francisco (to be published in Cancer this week), clinical staging errors may — at least in part — underlie the fact that the researchers were unable to demonstrate a clear link between clinical stage and risk for prostate cancer recurrence in patients initially diagnosed [...]
Filed under: Diagnosis, Management, Treatment | Tagged: accuracy, clinical, Diagnosis, prognosis, relevance, stage | 2 Comments »
At major academic medical centers and in at least one large clinical trial, the prostate cancer gene 3 or PCA3 test has appeared to work better than the total serum PSA test as a means to predict the presence of prostate cancer on biopsy.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PCA3, prognosis, PSA, risk | Leave a Comment »
According to a media release from Myriad Genetics, the company’s investigational genetic test (Prolaris™) can accurately predict prostate cancer-specific mortality at 10 years in men known to have clinically localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cancer-specific, genes, mortality, prognosis, PROLARIS, test | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site